|Mr. Peter L. Hoang MBA||Pres, CEO & Director||543.75k||N/A||1972|
|Mr. Anthony H. Kim||Chief Financial Officer||305.51k||N/A||1976|
|Mr. Michael J. Loiacono||Chief Accounting Officer, Treasurer & Sec.||287.98k||N/A||1966|
|Dr. Ann M. Leen||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Elizabeth Donnelly||Director of Admin.||N/A||N/A||N/A|
Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. In addition, the company is developing PolyStart, a proprietary nucleic acid-based antigen expression technology to enhance the ability of the immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Marker Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 3; Compensation: 9.